XO Life closes 4 million euros in new funding
The round was led by Fil Rouge Capital, including the participation from existing VC investors Sandwater, Grazia Equity, Vi Partners, and Bayern Kapital.
XO Life, the fastest-growing patient-pharma platform in Europe, today announced the successful closing of a €4 million funding round. The investment will be used to accelerate the company's growth trajectory toward Series A, meet increasing market demand, and drive its internationalization strategy.
The round was led by Fil Rouge Capital, including the participation from existing VC investors Sandwater, Grazia Equity, Vi Partners, and Bayern Kapital, alongside other current shareholders. Fil Rouge and their partner team bring decades of relevant operational experience, having managed billions in transactions and worked across multiple continents - making them a perfect addition to the next growth phase of XO Life.
XO Life’s proprietary brite™ platform is redefining how patients, healthcare professionals (HCPs), and pharmaceutical companies engage across the entire therapy journey. Unlike fragmented single‑solution apps, XO Life provides a unified meta‑platform that works across all medications, therapies, and conditions. It guides patients from initial orientation and diagnosis through therapy initiation and extends into continuous digital therapy monitoring. Designed as an open, scalable infrastructure, the platform is accessible to all pharmaceutical and medtech companies, enabling deployment across entire product portfolios and markets.
"This funding is a testament to the strong demand for a unified, high-quality patient-pharma platform," says Dr. Friderike Bruchmann, CEO at XO Life. "We are already working with more than 40 pharmaceutical companies, including three of the ten largest global players. This investment allows us to accelerate the development of our brite™ platform, leverage AI across all features, and automate pharma onboarding across entire portfolios."
In addition to its strong pharma footprint, the company has successfully expanded its ecosystem by collaborating with leading medical societies to ensure scientific excellence and strong patient adoption across different therapeutic areas.
“XO Life is addressing one of the most critical gaps in healthcare, connecting patients, providers and pharma in a novel patient centric and truly scalable way. We are impressed by the team’s execution to date and are confident that this funding round will accelerate the company’s growth trajectory.” – Partner, Morten E. Iversen, Sandwater.
The round was led by Fil Rouge Capital, including the participation from existing VC investors Sandwater, Grazia Equity, Vi Partners, and Bayern Kapital, alongside other current shareholders. Fil Rouge and their partner team bring decades of relevant operational experience, having managed billions in transactions and worked across multiple continents - making them a perfect addition to the next growth phase of XO Life.
XO Life’s proprietary brite™ platform is redefining how patients, healthcare professionals (HCPs), and pharmaceutical companies engage across the entire therapy journey. Unlike fragmented single‑solution apps, XO Life provides a unified meta‑platform that works across all medications, therapies, and conditions. It guides patients from initial orientation and diagnosis through therapy initiation and extends into continuous digital therapy monitoring. Designed as an open, scalable infrastructure, the platform is accessible to all pharmaceutical and medtech companies, enabling deployment across entire product portfolios and markets.
"This funding is a testament to the strong demand for a unified, high-quality patient-pharma platform," says Dr. Friderike Bruchmann, CEO at XO Life. "We are already working with more than 40 pharmaceutical companies, including three of the ten largest global players. This investment allows us to accelerate the development of our brite™ platform, leverage AI across all features, and automate pharma onboarding across entire portfolios."
In addition to its strong pharma footprint, the company has successfully expanded its ecosystem by collaborating with leading medical societies to ensure scientific excellence and strong patient adoption across different therapeutic areas.
“XO Life is addressing one of the most critical gaps in healthcare, connecting patients, providers and pharma in a novel patient centric and truly scalable way. We are impressed by the team’s execution to date and are confident that this funding round will accelerate the company’s growth trajectory.” – Partner, Morten E. Iversen, Sandwater.